Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China

OBJECTIVE: This study aimed to assess whether different clinical trial endpoints in pivotal trials of cancer drugs were associated with reimbursement decisions in China. MATERIALS AND METHODS: Cancer drugs marketed before June 30(th), 2021 with publicly available technical review reports for applica...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, Kexin, Qin, Huli, Feng, Yiman, Che, Hongxi, Ding, Jinxi, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730273/
https://www.ncbi.nlm.nih.gov/pubmed/36504948
http://dx.doi.org/10.3389/fpubh.2022.1062736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730273/
https://www.ncbi.nlm.nih.gov/pubmed/36504948
http://dx.doi.org/10.3389/fpubh.2022.1062736

Ejemplares similares